Ezetimibe and bile acid sequestrants: impact on lipoprotein metabolism and beyondCouture, Patricka,b; Lamarche, BenoîtbCurrent Opinion in Lipidology: June 2013 - Volume 24 - Issue 3 - p 227–232 doi: 10.1097/MOL.0b013e3283613a55 LIPID METABOLISM: Edited by Ernst J. Schaefer Abstract Author Information Purpose of review Several lines of evidence indicate that the enterocyte plays a pivotal role in cholesterol homeostasis. The development of the selective inhibitor of cholesterol absorption ezetimibe and bile acid sequestrants (BAS) interrupting the enterohepatic circulation of bile salts has expanded the options for preventing and treating cardiovascular disease. We discuss here a selection of recently published studies that evaluated the effects of ezetimibe and BAS on lipoprotein metabolism. Recent findings Although significant progress has been made in recent years in elucidating the impacts of ezetimibe and BAS on lipoprotein metabolism, underlying mechanisms are not completely understood. Important new insights have been provided by using in-vivo kinetic studies of apolipoproteins labelled with a stable isotope. Other reports indicated that ezetimibe and BAS modulate the expression of several key genes involved in intestinal lipoprotein metabolism. Many of these effects have been related to the local effects of ezetimibe and BAS on intestinal cholesterol homeostasis. Summary A substantial effort is being made by researchers to fully understand the mechanisms by which ezetimibe and BAS improve lipid profile. The efficacy of combination therapy of statins with ezetimibe or BAS for the prevention of cardiovascular disease remains to be confirmed in clinical endpoint studies. aLipid Research Center, Laval University Medical Center bInstitute of Nutrition and Functional Foods (INAF), Laval University, Quebec City, Canada Correspondence to Patrick Couture, MD, FRCP(C), PhD, Institute of Nutrition and Functional Foods (INAF), 2440, Hochelaga Blvd, Laval University, Quebec City, G1V 0A6, Canada. Tel: +418 654 2106; fax: +418 317 1320; e-mail: firstname.lastname@example.org © 2013 Lippincott Williams & Wilkins, Inc.